INMED PHARMACEUTICALS INC. Foreign Currency Transaction Gain (Loss), Unrealized
INMED PHARMACEUTICALS INC. (INM) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$7.15 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was $20.58K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$24.48K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$1.89K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was -$1.36K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), unrealized for fiscal 2023 was -$48.17K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), unrealized for fiscal 2022 was -$117.55K, a 127.31% decline from fiscal 2021.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), unrealized for fiscal 2021 was $430.44K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), unrealized for fiscal 2020 was -$419.84K.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 3 month as first filed | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $20.58K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | -$3.90K derived: sum of 2 quarters · filed 2026-09-09 | -$5.79K derived: sum of 3 quarters · filed 2026-09-09 | -$7.15K S-4/A · filed 2026-09-09 | ||
| 2026-03-31 | -$24.48K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | -$26.37K derived: sum of 2 quarters · filed 2026-07-02 | -$27.73K S-4 · filed 2026-07-02 | -$58.75K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-12-31 | -$1.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$3.25K 10-Q · filed 2026-02-11 | -$34.27K derived: sum of 3 quarters · filed 2026-09-09 | -$58.81K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-09-30 | -$1.36K 10-Q · filed 2025-11-06 | -$32.38K derived: sum of 2 quarters · filed 2026-09-09 | -$56.91K derived: sum of 3 quarters · filed 2026-09-09 | -$71.98K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-06-30 | -$31.02K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | -$55.56K derived: sum of 2 quarters · filed 2026-09-09 | -$70.62K derived: sum of 3 quarters · filed 2026-09-09 | -$75.89K S-4/A · filed 2026-09-09 | -$75.93K S-4 · filed 2026-07-02 | |
| 2025-03-31 | -$24.54K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | -$39.61K derived: sum of 2 quarters · filed 2026-07-02 | -$44.88K S-4 · filed 2026-07-02 | |||
| 2024-12-31 | -$15.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$20.34K 10-Q · filed 2026-02-11 | ||||
| 2024-09-30 | -$5.27K 10-Q · filed 2025-11-06 | $19.31K 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | -$12.26K S-4 · filed 2026-07-02 | -$61.92K 10-K · filed 2024-09-30 | ||||
| 2023-12-31 | $59.90K 10-Q · filed 2024-02-13 | $11.44K 10-Q · filed 2024-02-13 | $42.55K derived: sum of 3 quarters · filed 2024-11-14 | $39.82K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-09-30 | -$48.46K 10-Q · filed 2024-11-14 | -$17.34K derived: sum of 2 quarters · filed 2024-11-14 | -$20.08K derived: sum of 3 quarters · filed 2024-11-14 | $159.00 derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $31.11K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $28.38K derived: sum of 2 quarters · filed 2024-09-30 | $48.62K derived: sum of 3 quarters · filed 2024-09-30 | -$48.17K 10-K · filed 2024-09-30 | ||
| 2023-03-31 | -$2.73K 10-Q · filed 2023-05-15 | $17.50K derived: sum of 2 quarters · filed 2024-02-13 | -$79.29K 10-Q · filed 2023-05-15 | -$148.73K derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-12-31 | $20.24K 10-Q · filed 2024-02-13 | -$76.55K 10-Q · filed 2024-02-13 | -$146.00K derived: sum of 3 quarters · filed 2024-02-13 | -$113.00K derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-09-30 | -$96.79K 10-Q · filed 2022-11-14 | -$166.23K derived: sum of 2 quarters · filed 2023-09-29 | -$133.24K derived: sum of 3 quarters · filed 2023-09-29 | -$130.23K derived: sum of 4 quarters · filed 2023-09-29 | ||
| 2022-06-30 | -$69.44K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | -$36.45K derived: sum of 2 quarters · filed 2023-09-29 | -$33.44K derived: sum of 3 quarters · filed 2023-09-29 | -$117.55K 10-K · filed 2023-09-29 | ||
| 2022-03-31 | $33.00K 10-Q · filed 2023-05-15 | $36.00K derived: sum of 2 quarters · filed 2023-05-15 | -$48.11K 10-Q · filed 2023-05-15 | -$48.11K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $3.01K 10-Q · filed 2023-02-17 | -$81.11K 10-Q · filed 2023-02-17 | -$81.11K derived: sum of 3 quarters · filed 2023-02-17 | -$81.11K derived: sum of 4 quarters · filed 2023-02-17 | ||
| 2021-09-30 | -$84.11K 10-Q · filed 2022-11-14 | -$84.11K derived: sum of 2 quarters · filed 2022-11-14 | -$84.11K derived: sum of 3 quarters · filed 2022-11-14 | $216.93K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $0.00 derived: sum of 2 quarters · filed 2022-09-23 | $301.04K derived: sum of 3 quarters · filed 2022-09-23 | $430.44K 10-K · filed 2022-09-23 | ||
| 2021-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $301.04K derived: sum of 2 quarters · filed 2022-05-13 | $430.44K 10-Q · filed 2022-05-13 | $696.44K derived: sum of 4 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $301.04K 10-Q · filed 2022-02-14 | $430.44K 10-Q · filed 2022-02-14 | $696.44K derived: sum of 3 quarters · filed 2022-02-14 | -$21.07K derived: sum of 4 quarters · filed 2022-02-14 | ||
| 2020-09-30 | $129.40K 10-Q · filed 2021-11-10 | $395.40K derived: sum of 2 quarters · filed 2021-11-10 | -$322.11K derived: sum of 3 quarters · filed 2021-11-10 | $28.04K derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $266.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | -$451.51K derived: sum of 2 quarters · filed 2021-09-24 | -$101.36K derived: sum of 3 quarters · filed 2021-09-24 | -$419.84K 10-K · filed 2021-09-24 | ||
| 2020-03-31 | -$717.51K 10-Q · filed 2021-05-13 | -$367.36K derived: sum of 2 quarters · filed 2021-05-13 | -$685.83K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $350.15K 10-Q · filed 2021-02-11 | $31.68K 10-Q · filed 2021-02-11 | ||||
| 2019-09-30 | -$318.48K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |